Key Advances in the Treatment
and Management of Asthma

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2016 Fall Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from December 15, 2016 to December 31, 2017

Instructions for CME/CNE: Listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.  To print or save your certificate, you will need to click on the “download” button and either print or save.

These presentations require Adobe Flash Player.  You can download it here.
 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from Teva Pharmaceuticals

PLEASE CLICK HERE TO VIEW THE PRESENTATION IN FLASH

PLEASE CLICK HERE TO VIEW THE PRESENTATION IN HTML5

PLEASE CLICK HERE FOR EVALUATION and POST-TEST

Description
As progress is made in the scientific understanding of airway inflammation and narrowing, the prevalence of asthma continues to rise, and there is a clear need for improved diagnosis and more aggressive and effective treatment. Consequently, many studies show insufficient patient adherence to prescribed and behavioral treatment regimens, leading to a major cause of poor clinical outcomes. Patients with asthma often do not have their asthma well controlled due to many different barriers including: age, socioeconomic status, complexity of the treatment plan and lack of education. For improved asthma management, these factors must be addressed and solutions sought, so that adherence can be more accurately targeted and treated through increased assessment.

While there is no cure for asthma, it is possible to manage the disease successfully through a number of behavioral changes and therapies, such as decreasing exposure to allergens and by using an inhaled corticosteroids (ICS) and/or long-acting beta-2 agonists. There are also several new therapies emerging in clinical trials which aim to help control and treat asthma. These treatments have shown to improve lung function and decrease rescue bronchodilator use. The treatment goals for most asthmatic patients are to reduce the frequency and intensity of symptoms and reduce the risk of future asthma attacks, as these attacks lead to the decline in lung function.

Upon Completion of this activity, participants will be able to:

  • Assess recent clinical data on the efficacy and safety of current and emerging treatment options for asthma, including the mechanisms of action for biologic drugs

  • Examine the evidence base for disease monitoring tools and appropriate treatment selection for asthma control

  • Discuss appropriate and effective ways to assess asthma control to improve patient adherence, self-management, and overall quality of life in asthma patients

  • Analyze different options for improving asthma control in patients with uncontrolled, persistent allergic asthma

  • Identify the potential benefits and the role of therapies that target the inflammatory component of allergic asthma
     

Faculty: David Lang, MD
Professor of Medicine & Chair
Department of Allergy & Clinical Immunology; Co-Director of the Asthma Center
Cleveland Clinic

Disclosure:

Dr. Lang has received honoraria from, has carried out clinical research with, and/or has served as a consultant for Adamis, AstraZeneca, Genentech, GlaxoSmithKline, Merck, and Novartis. This presentation does not include discussion of off-label uses of FDA approved products, but does mention agents that are not FDA approved. His presentation has been peer reviewed for any bias.
 
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

The National Association of Managed Care Physicians designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses who complete this activity and turn in a validation form will receive up to 1 credit in continuing nursing education.

The American Board of Managed Care Nurses has approved this activity for a maximum of 1 contact hour towards CMCN recertification.

This presentation is supported by an educational grant from Teva Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.